Тёмный

The Allogeneic Future with Poseida's Kristin Yarema, Ph.D. 

Life Science Connect
Подписаться 2 тыс.
Просмотров 190
50% 1

Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. Dr. Yarema is the newly-appointed CEO at Poseida Therapeutics, a company we first covered with founding CEO Eric Ostertag, Ph.D. On this episode of the Business of Biotech, we'll learn about Dr. Yarema, how she earned the company's reins, how Poseida is positioning itself to crack the allogeneic CAR T code, and how strategic collaborations with the likes of Astellas and Roche are fueling the effort.
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple...
Spotify - open.spotify.c...
RU-vid - • The Business Of Biotec...

Опубликовано:

 

29 окт 2024

Поделиться:

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист
Посмотреть позже
Комментарии    
Далее
Nightmare | Update 0.31.0 Trailer | Standoff 2
01:14
Просмотров 699 тыс.
Why Hermès Is Growing While LVMH And Gucci Decline
9:12
AI's 'Existential Threat' to Humans
13:26
Просмотров 37 тыс.
What Comes After Generative AI?
19:47
Просмотров 10 тыс.